Bioinformatics analysis of programmed cell death ligand 1 co-expression genes and their regulatory network in head and neck squamous cell carcinoma

doi:10.7518/hxkq.2019.05.012

Abstract

Abstract:

Objective This study aimed to construct a network of programmed celldeath ligand 1 (PD-L1) co-expression genes and screen potential biomarkers for PD-L1 expression in head and neck squamous cell carcinoma (HNSCC) by bioinformatics analysis. Moreover, the genes and pathways participating in PD-L1 and regulating the tumor immune status were determined. Methods The HNSCC transcriptomic dataset in TCGA was selected to retrieve gene sets on the cBioPortal platform, where PD-L1 co-expressional genes were acquired. With these genes, GO-BP, KEGG, and string analyses were performed in R clusterProfiler. Cytoscape was used for network analysis and hub gene screening. Results A total of 117 co-expression genes were obtained, most of which were enriched in immune regulation and response to viral processes. Node degree analysis indicated that STAT1, IFNG, CXCL10, CCR5, FCGR3A, CXCL9, GBP5, CD86, GZMB, IRF1 were the highest connected genes and functioned as hub genes. Survival analysis of these hub genes resulted in CCR5, CXCL9, and GZMB as the prognostic biomarkers for patients with HNSCC, all of which were involved in immune regulation and their expression levels were related to PD-L1 (Pearson correlation coefficient was 0.30, 0.35, 0.39; P<0.01). High expression levels of these three hub genes were protective factors in patients with HNSCC. Conclusion PD-L1 co-expression hub genes are related to immunity, among which CCR5, CXCL9, and GZMB are prognostic markers with the possibility to be involved in programmed cell death protein 1 (PD-1)/PD-L1-induced tumor immune escape. These genes provide new clues to study the mechanism and precision target medicine of PD-1/PD-L1 in HNSCC.

Key words: head and neck squamous cell carcinoma, bioinformatics analysis, programmed cell death ligand 1, programmed cell death protein 1

CLC Number:

Q786

Yang Lisa,Shi Congyu,Liang Yuhao,Liu Tong,Hou Xiaoru,Tian Xudong,Wang Xiaoyi. Bioinformatics analysis of programmed cell death ligand 1 co-expression genes and their regulatory network in head and neck squamous cell carcinoma[J]. West China Journal of Stomatology, 2019, 37(5): 516-520.

Figures/Tables 5

References 16

[1]	Johnson NW, Jayasekara P, Amarasinghe AA . Squamous cell carcinoma and precursor lesions of the oral cavity: epidemiology and aetiology[J]. Periodontology 2000, 2011,57(1):19-37.
[2]	Szklarczyk D, Morris JH, Cook H , et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible[J]. Nucleic Acids Res, 2017,45(Database issue):D362-D368.
[3]	Okazaki T, Honjo T . The PD-1-PD-L pathway in immunological tolerance[J]. Trends Immunol, 2006,27(4):195-201.
[4]	Valentini AM, Di Pinto F, Cariola F , et al. PD-L1 expression in colorectal cancer defines three subsets of tumor immune microenvironments[J]. Oncotarget, 2018,9(9):8584-8596.
[5]	Wu P, Wu D, Li L , et al. PD-L1 and survival in solid tumors: a meta-analysis[J]. PLos One, 2015,10(6):e0131403.
[6]	Lei ZG, Ren XH, Wang SS , et al. Immunocompromised and immunocompetent mouse models for head and neck squamous cell carcinoma[J]. Onco Targets Ther, 2016,9:545-555.
[7]	Heineman TE, Widman A, Kuan EC , et al. The genetic landscape of programmed death ligand-1 (PD-L1) alterations in head and neck cancer[J]. Laryngoscope Investig Otolaryngol, 2017,2(3):99-103.
[8]	Ferris RL, Blumenschein G Jr, Fayette J , et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck[J]. New Eng J Med, 2016,375(19):1856-1867.
[9]	Wowk ME, Trapani JA . Cytotoxic activity of the lymphocyte toxin granzyme B[J]. Microbes Infect, 2004,6(8):752-758.
[10]	Du W, Leigh ND, Bian G , et al. Granzyme B contributes to the optimal graft-versus-tumor effect mediated by conventional CD4+T cells[J]. J Immunol Res Ther, 2016,1(1):22-28.
[11]	Jie HB, Srivastava RM, Argiris A , et al. Increased PD-1+ and TIM-3+ TILs during cetuximab therapy inversely correlates with response in head and neck cancer patients[J]. Cancer Immunol Res, 2017,5(5):408-416.
[12]	Chuang JY, Yang WH, Chen HT , et al. CCL5/CCR5 axis promotes the motility of human oral cancer cells[J]. J Cell Physiol, 2010,220(2):418-426.
[13]	da Silva JM, Moreira Dos Santos TP, Sobral LM , et al. Relevance of CCL3/CCR5 axis in oral carcinogenesis[J]. Oncotarget, 2017,8(31):51024-51036.
[14]	Chen KQ, Bao ZY, Tang P , et al. Chemokines in homeostasis and diseases[J]. Cellular and Molecular Immunology, 2018,15(4):324-334.
[15]	Lai WY, Huang BT, Wang JW , et al. A novel PD-L1-targeting antagonistic DNA aptamer with antitumor effects[J]. Mol Ther Nucleic Acids, 2016,5(12):e397.
[16]	De Waele J, Marcq E, Van Audenaerde JR , et al. Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade[J]. Oncoimmunol, 2017,7(3):e1407899